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underlying difference in the experience of the condition.
A second pre-test is being conducted using all items
ranked highly across both countries to determine if there
are any differences between countries.
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OBJECTIVE: To assess the cost-effectiveness of the
various oral triptan tablets currently available in the US
for the acute treatment of migraine headache, and to esti-
mate the prices at which eletriptan and frovatriptan
would need to enter the market in order to be competi-
tive. METHODS: This study uses a decision model 
to evaluate the cost-effectiveness of oral triptan tablets.
Average wholesale prices were obtained from the 2002
Drug Topics Red Book. Efﬁcacy data was derived from
over 65 double-blind, placebo-controlled clinical trials
for almotriptan, eletriptan, frovatriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan. Using patient
reports for pain relief at 1, 2, and 4 hours post-dose, as
well as headache recurrence within 24 hours, and serious
side effects, probability estimates for these parameters
were calculated by weighting each clinical trial estimate
by its sample size. Success was deﬁned as pain relief
within 2 hours without headache recurrence within 24
hours and without a serious side effect. Threshold analy-
ses were conducted to determine the prices of eletriptan
and frovatriptan. RESULTS: All triptans had similar side
effect proﬁles, but varied markedly in price and efﬁcacy.
Almotriptan was the most cost-effective triptan ($35.47
per successful outcome for 12.5mg tablets, $40.92 for
6.25mg), followed by rizatriptan ($44.53 for 10mg,
$48.68 for 5mg) and zolmitriptan (2.5mg $48.88, 5mg
$49.43). All doses of sumatriptan and naratriptan were
greater than $50 per successful outcome. To be competi-
tive with almotriptan, eletriptan would need to be priced
around $9 per tablet for the 80mg dose, and $11 per
tablet for the 40mg dose. Frovatriptan 2.5mg, on the
other hand, needs to be priced at $2 per tablet. CON-
CLUSION: At $10.55 per tablet, almotriptan was the
most cost-effective triptan currently marketed in the US.
The price for eletriptan must be $11 or less to be equally
cost-effective.
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OBJECTIVES: A dynamic multistate model was used to
project the future burden of Chronic Obstructive 
Pulmonary Disease (COPD) in the Netherlands in rela-
tion to trends in demography and smoking. With the help
of the model, different projections can be made that vary
according to assumptions about future developments in
smoking, about demography, and about COPD preva-
lence. METHODS: First, a simple prevalence projection
of COPD was made, applying observed 1994 5-year
prevalence rates on a projection of the population in
2010. That is, the prevalence projection uses prevalence
of for instance the 55- to 59-year-old in 1994 and popu-
lation projections to ﬁnd prevalence of this same age
group 10 years later. Second, a dynamic model that
accounts for age and gender dependent incidence of
COPD and trends in smoking prevalence was used. With
the model we made incidence and smoking based projec-
tions, one assuming that smoking would remain at its
1994 levels and another using a scenario for future
smoking based on observed trends in start and stop rates.
The model basically uses prevalence of the 45- to 49-year-
old in 1994 together with incidence and mortality to
project prevalence of the 55- to 59-year-old 10 years later.
RESULTS: The prevalence projections ﬁnd an increase in
COPD total prevalence of 27%. The model projections
ﬁnd a prevalence increase of 70% and 68%, with the
lower assuming smoking at its 1994 levels. In this speciﬁc
case, the prevalence projections ﬁnd increases in COPD
that are half those projected by the model. CONCLU-
SIONS: The results demonstrate differences between the
extrapolation of prevalence rates using population pro-
jections and more complex projections with a dynamic
model. These differences cannot solely be explained by
trends in smoking prevalence: this is shown by the model
projection with constant smoking prevalence. In this spe-
ciﬁc case, prevalence extrapolations underestimate future
prevalence.
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OBJECTIVE: Hormone replacement therapy (HRT) is
the standard therapy aimed at reducing fracture risk 
in postmenopausal women in Australia, although newer
therapies such as the bisphosphonates, calcitriol and
raloxifene are used in osteoporotic women with radi-
ographically deﬁned fracture due to minimal trauma.
There are many women, however, for whom HRT is inap-
